Table 1.
Prevalence of insomnia drugs prescribed at US outpatient visits in 2006
| Insomnia drugs | Generic equivalent code | Weighted frequency | Percentage (%) |
|---|---|---|---|
| FDA-approved benzodiazepine hypnotics | |||
| Temazepam (Restoril®) | d00384 | 2,644,074 | 8.7% |
| Estazolam (Prosom®) | d00915 | 108,135 | 0.4% |
| Triazolam (Halcion®) | d00397 | 535,258 | 1.8% |
| Flurazepam (Dalmane®) | d00238 | 249,686 | 0.8% |
| Quazepam (Doral®) | d00917 | 0 | 0% |
| FDA-approved nonbenzodiazepine z-hypnotics | |||
| Zolpidem (Ambien®) | d00910 | 9,996,496 | 32.8% |
| Zaleplon (Sonata®) | d04452 | 265,363 | 0.9% |
| Eszopiclone (Lunesta®) | d05421 | 2,290,378 | 7.5% |
| Selective melatonin receptor agonist | |||
| Ramelteon (Rozerem®) | d05778 | 614,907 | 2.0% |
| Non FDA-approved antidepressants | |||
| Trazodone (Desyrel®) | d00395 | 5,435,674 | 17.9% |
| Amitriptyline (Elavil®) | d00146 | 4,413,467 | 14.5% |
| Mirtazapine (Remeron®) | d04025 | 1,761,523 | 5.8% |
| Nortriptyline (Aventyl®) | d00144 | 1,424,346 | 4.7% |
| Doxepin (Sinequan®) | d00217 | 695,369 | 2.3% |
| Total | 30,434,676 | 100.0% | |